Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimalarial compounds: from bench to bedside.

Piero L Olliaro1, Walter R J Taylor

  • 1UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, World Health Organization, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland. olliarop@who.int

The Journal of Experimental Biology
|September 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Natural direct effects of vaccines and post-vaccination behaviour.

Vaccine·2026
Same author

Analysis of the effect of primaquine dose on efficacy, safety, and tolerability in patients with Plasmodium vivax malaria in Ethiopia: a systematic review and individual patient data meta-analysis.

Malaria journal·2026
Same author

Effectiveness of stigma reduction interventions and outbreak response adaptations in infectious disease outbreaks: a systematic review.

Frontiers in public health·2026
Same author

Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis.

Malaria journal·2025
Same author

Plasma folate dynamics in Plasmodium falciparum-infected African children treated with artemisinin combination therapy and single low-dose primaquine or placebo.

Malaria journal·2025
Same author

Mixing methods: How listening to researchers, healthcare workers, and community members can improve the design of studies testing medical innovations for Neglected Tropical Diseases.

PLoS neglected tropical diseases·2025

Drug resistance threatens malaria control. New combination therapies, particularly artemisinin-based ones, offer enhanced efficacy and a strategy to combat resistance, ensuring longer drug lifespans.

Area of Science:

  • * Malariology and Tropical Medicine
  • * Pharmaceutical Sciences and Drug Development

Background:

  • * Drug-resistant malaria parasites represent a significant global health threat, jeopardizing current malaria control strategies.
  • * Historical reliance on quinoline and antifolate drugs has been undermined by emerging resistance, necessitating novel therapeutic approaches.
  • * Artemisinin-type compounds have recently gained prominence, but their long-term efficacy is also threatened by resistance.

Purpose of the Study:

  • * To review current antimalarial drug developments and emerging resistance patterns.
  • * To summarize recent clinical research on artemisinin-based combination therapies (ACTs).
  • * To highlight the need for effective, affordable, and long-lasting antimalarial drugs.

Main Methods:

  • * Literature review of antimalarial drug development and clinical trials.

Related Experiment Videos

  • * Analysis of resistance trends and the impact of drug combinations.
  • * Synthesis of data on the efficacy and safety of artemisinin-based combinations.

    • Main Results:

    • * The antimalarial drug pipeline shows activity, but novelty is limited, with many projects relying on established drug classes.
    • * Drug combinations, especially ACTs, demonstrate improved efficacy and mutual resistance protection without increased toxicity.
    • * Cure rates for combinations are variable, influenced by the level of resistance to the partner drug.

    Conclusions:

    • * Artemisinin-based combination therapies are crucial for enhancing malaria treatment efficacy and combating drug resistance.
    • * Fixed-dose combination formulations are being developed to improve adherence and ease of use in endemic areas.
    • * Continued research and development are essential to ensure a sustainable supply of effective antimalarial drugs.